Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival.

Tahover, Esther; Segal, Amiel; Isacson, Rut; Rosengarten, Ora; Grenader, Tal; Gips, Maya; Cherny, Nathan; Heching, Norman I; Mesika, Lior; Catane, Raphael; Gabizon, Alberto

Tahover, Esther; Segal, Amiel; Isacson, Rut; Rosengarten, Ora; Grenader, Tal; Gips, Maya; Cherny, Nathan; Heching, Norman I; Mesika, Lior; Catane, Raphael; Gabizon, Alberto.

Affiliation

Tahover E; aOncology Institute, Shaare Zedek Medical Center bSchool of Medicine, Hebrew University, Jerusalem, Israel.

Anticancer Drugs ; 28(7): 787-794, 2017 08.

Article in En | MEDLINE | ID: mdl-28562379

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide/administration & dosage; Dexrazoxane/administration & dosage; Dexrazoxane/adverse effects; Doxorubicin/administration & dosage; Doxorubicin/adverse effects; Female; Humans; Middle Aged; Retrospective Studies; Survival Analysis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Anticancer Drugs Journal subject: ANTINEOPLASICOS Year: 2017 Document type: Article Affiliation country: Israel Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google